Biologic agents in juvenile spondyloarthropathies

Table 1 Anti-TNFα in JSpA

Source	Drug	JSpA patients (n)	Study duration	Outcome^a	Study design
Henrickson [37]	ETNERCEPT	8	24 months	improvement^b	Open-label Uncontrolled
Tse [38]	ETANERCEPT	2
	INFLIXIMAB	8	12 months	improvement	Open-label Uncontrolled
Sulpice [39]		20 (23 treatments)
	ETANERCEPT	19	12 months	improvement	Retrospective Cohort
	INFLIXIMAB	3
	ADALIMUMAB	1
Otten [40]		22 (24 treatments)
	ETANERCEPT	20
	INFLIXIMAB	2	24 months	improvement	Multicenter Observational Register
	ADALIMUMAB	2
Horneff [41]	ADALIMUMAB	17	6 months	improvement	Double-Blind Placebo-controlled
Horneff [42]	ETANERCEPT	122	3 months	improvement	Open-label
					Uncontrolled
Burgos Vargas [43]	ADALIMUMAB	46	12 months	improvement	Double-Blind Placebo-controlled
Hugle B [44]	INFLIXIMAB	10	84 months		Open-label
	ETANERCEPT	6		improvement	Observational
Horneff G [45]	ETANERCEPT	41	12 months	improvement	Double-Blind Placebo- controlled

References:
^aOutcome measures observed were different: morning stiffness, active joints count, tender enthesal count, ESR, ACRped 30/50/70/90, inactive disease, ASAS 20/40, CHAQ, BASFI
^bImprovement was defined according to each author's criteria as decrease in morning stiffness, active joints, tender enthesal count and ESR, improvement in functional capacity (CHAQ and/or BASFI). Also tools used in improvement assessment were ACR ped, BASDAI, JADAS 10, ASAS. inactive disease and remission

ISSN: 1546-0096